导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -3.73% | 3242/4773 |
| 近一周 | -2.14% | 2480/5458 |
| 近一月 | -2.84% | 1741/5421 |
| 近一季 | -2.48% | 1701/5205 |
| 近半年 | -7.80% | 3344/4920 |
| 近一年 | -2.29% | 3035/4361 |
| 近两年 | 32.62% | 2215/2954 |
| 近三年 | 9.06% | 1772/2253 |
| 成立以来 | 47.25% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.63% 2396/4961 |
0.01% 3223/5312 |
- - |
- - |
| 2025 | 12.05% 2709/4813 |
-0.76% 2394/3635 |
-2.09% 3308/4076 |
16.41% 2653/4524 |
-0.94% 2735/4813 |
| 2024 | 10.31% 1421/3463 |
2.37% 788/2808 |
-3.96% 1444/3014 |
18.14% 1051/3129 |
-5.02% 2518/3463 |
| 2023 | -5.73% 768/2656 |
6.21% 711/2280 |
-4.73% 1265/2385 |
0.03% 396/2515 |
-6.87% 1954/2655 |
| 2022 | -17.71% 622/2207 |
-10.34% 393/1919 |
1.81% 1416/2016 |
-12.26% 684/2113 |
2.75% 846/2208 |
| 2021 | -3.21% 894/1822 |
0.84% 274/1255 |
-1.04% 1156/1330 |
-2.36% 567/1466 |
-0.67% 1264/1822 |
| 2020 | 23.18% 657/1250 |
-11.65% 845/1028 |
11.80% 715/1067 |
10.55% 536/1164 |
12.80% 431/1184 |
| 2019 | 47.58% 119/1092 |
33.97% 120/739 |
-1.45% 305/788 |
0.63% 499/850 |
11.08% 81/918 |
| 2018 | - - |
- - |
- - |
-4.72% 345/660 |
-9.66% 156/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 嘉实深证基本面120联接C VS. 长安沪深300非周期A(740101) |